Palvella Therapeutics Announces Positive Topline Results from Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Tre…

(11/15 participants) improved on the Overall Cutaneous Venous Malformations Investigator Global Assessment (Overall ...